Gestational diabetes screening with the new IADPSG guidelines: a cost-effectiveness analysis

被引:84
|
作者
Mission, John F. [1 ]
Ohno, Mika S. [2 ]
Cheng, Yvonne W. [3 ]
Caughey, Aaron B. [1 ]
机构
[1] Oregon Hlth & Sci Univ, Dept Obstet & Gynecol, Portland, OR 97201 USA
[2] Santa Clara Valley Med Ctr, Dept Obstet & Gynecol, San Jose, CA 95128 USA
[3] Univ Calif San Francisco, Sch Med, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA USA
基金
美国国家卫生研究院;
关键词
cost effectiveness; decision analysis; gestational diabetes; International Association of Diabetes in Pregnancy Study Group guidelines; 2-hour glucose tolerance test; INTERNATIONAL ASSOCIATION; CESAREAN DELIVERY; MELLITUS; PREGNANCY; DIAGNOSIS; WOMEN; HYPERGLYCEMIA; PREVENTION; MACROSOMIA; TRIAL;
D O I
10.1016/j.ajog.2012.06.048
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
OBJECTIVE: This study investigates the cost effectiveness of gestational diabetes mellitus screening using the new International Association of Diabetes in Pregnancy Study Group (IADPSG) guidelines. STUDY DESIGN: A decision analytic model was built comparing routine screening with the 2-hour (2h) oral glucose tolerance test (OGTT) vs the 1-hour glucose challenge test. All probabilities, costs, and benefits were derived from the literature. Base case, sensitivity analyses, and a Monte Carlo simulation were performed. RESULTS: Screening with the 2h OGTT was more expensive, more effective, and cost effective at $61,503/quality-adjusted life year. In a 1-way sensitivity analysis, the more inclusive IADPSG diagnostic approach remained cost effective as long as an additional 2.0% or more of patients were diagnosed and treated for gestational diabetes mellitus. CONCLUSION: Screening at 24-28 weeks' gestational age under the new IADPSG guidelines with the 2h OGTT is expensive but cost effective in improving maternal and neonatal outcomes. How the health care system will provide expanded care to this group of women will need to be examined.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] Universal fetal echocardiography for pre-gestational diabetes: a cost-effectiveness analysis
    Savitsky, Leah M.
    Albright, Catherine M.
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2021, 224 (02) : S49 - S49
  • [32] Oral hypoglycemic agents in the treatment of gestational diabetes mellitus: a cost-effectiveness analysis
    Davitt, Caroline C.
    Hersh, Alyssa R.
    Packer, Claire H.
    Munn, Allison
    Vinson, Abigail
    Caughey, Aaron B.
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2020, 222 (01) : S450 - S451
  • [33] Cost-effectiveness of gestational diabetes screening including prevention of type 2 diabetes: application of the GeDiForCE model in Australia
    Beilby, Hannah
    Yang, Fan
    Gannon, Brenda
    McIntyre, Harold David
    JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE, 2022, 35 (25): : 8286 - 8293
  • [34] COST-EFFECTIVENESS ANALYSIS OF HEMOCULT SCREENING
    PEDERSEN, KM
    KRONBORG, O
    SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 1986, 46 : 67 - 67
  • [35] Cost-effectiveness analysis of screening for GDM
    Van Leeuwen, Marsha
    Vijgen, Sylvia
    Opmeer, Brent C.
    Evers, Inge
    Mol, Ben Willem
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2009, 201 (06) : S109 - S109
  • [36] SCREENING FOR SCOLIOSIS - A COST-EFFECTIVENESS ANALYSIS
    MONTGOMERY, F
    PERSSON, U
    BENONI, G
    WILLNER, S
    LINDGREN, B
    SPINE, 1990, 15 (02) : 67 - 70
  • [37] Cost-effectiveness analysis in mammography screening
    vonFournier, D
    RADIOLOGE, 1996, 36 (04): : 300 - 305
  • [38] GLAUCOMA SCREENING - A COST-EFFECTIVENESS ANALYSIS
    GOTTLIEB, LK
    SCHWARTZ, B
    PAUKER, SG
    SURVEY OF OPHTHALMOLOGY, 1983, 28 (03) : 206 - 228
  • [39] Cost-effectiveness of controlling gestational diabetes mellitus: a systematic review
    Fitria, Najmiatul
    van Asselt, Antoinette D. I.
    Postma, Maarten J.
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2019, 20 (03): : 407 - 417
  • [40] Cost-effectiveness of controlling gestational diabetes mellitus: a systematic review
    Najmiatul Fitria
    Antoinette D. I. van Asselt
    Maarten J. Postma
    The European Journal of Health Economics, 2019, 20 : 407 - 417